|
| 36600045 | Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer. | Prostate Cancer Prostatic Dis | 2024 |
| 37442672 | Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation. | Eur Urol Oncol | 2024 |
| 36269935 | Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. | J Clin Oncol | 2023 |
| 37910103 | Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis. | JAMA Netw Open | 2023 |
| 37393115 | Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies. | Eur Urol | 2023 |
| 37179085 | Beyond Diversity Toward Inclusion, Belonging, and Safety. | Int J Radiat Oncol Biol Phys | 2023 |
| 37104748 | Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. | J Clin Oncol | 2023 |
| 37104723 | Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial. | J Clin Oncol | 2023 |
| 37137444 | Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. | Int J Radiat Oncol Biol Phys | 2023 |
| 36592721 | Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 36522277 | Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel. | Pract Radiat Oncol | 2023 |
| 36579470 | Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126. | Cancer | 2023 |
| 36736921 | Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415. | Int J Radiat Oncol Biol Phys | 2023 |
| 36711067 | Prostate cancer extracellular vesicle digital scoring assay - a rapid noninvasive approach for quantification of disease-relevant mRNAs. | Nano Today | 2023 |
| 36898417 | The American Society for Radiation Oncology Workforce Taskforce Review of the United States Radiation Oncology Workforce Analysis. | Int J Radiat Oncol Biol Phys | 2023 |
| 36596347 | Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. | Int J Radiat Oncol Biol Phys | 2023 |
| 36657498 | Recent Trends in Medicare Payments for Outpatient Cancer Care at the End of Life. | Int J Radiat Oncol Biol Phys | 2023 |
| 34740768 | Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526). | Int J Radiat Oncol Biol Phys | 2022 |
| 35737923 | Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. | J Clin Oncol | 2022 |
| 35675855 | The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. | Int J Radiat Oncol Biol Phys | 2022 |
| 35377775 | Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations. | J Urol | 2022 |
| 35469702 | High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. | Eur Urol | 2022 |
| 35569466 | The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. | Lancet | 2022 |
| 35690354 | Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Quality Measures Initiative. | Pract Radiat Oncol | 2022 |
| 35813938 | Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment. | Clin Transl Radiat Oncol | 2022 |
| 35776901 | Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. | JCO Clin Cancer Inform | 2022 |
| 35934601 | Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). | Eur Urol | 2022 |
| 35963472 | ASTRO Supports Access to Evidence-Based Cancer Care for All Patients, Regardless of Pregnancy Status, and Protection for Physicians Recommending and Providing Evidence-Based Care. | Int J Radiat Oncol Biol Phys | 2022 |
| 36116477 | The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply. | Lancet | 2022 |
| 34919884 | Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. | Int J Radiat Oncol Biol Phys | 2022 |
| 35311991 | Quantitative Nodal Burden and Mortality Across Solid Cancers. | J Natl Cancer Inst | 2022 |
| 35051385 | Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. | Lancet Oncol | 2022 |
| 34694160 | Development and Validation of an Improved Pathological Nodal Staging System in Men with Prostate Cancer. | J Urol | 2022 |
| 34481017 | Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. | Int J Radiat Oncol Biol Phys | 2022 |
| 32861817 | NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2021 |
| 33852571 | Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. | PLoS One | 2021 |
| 33570548 | Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 33712498 | Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2). | Clin Cancer Res | 2021 |
| 33818052 | Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics. | Oncology (Williston Park) | 2021 |
| 33662287 | Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. | Lancet Oncol | 2021 |
| 34964855 | Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis. | JAMA Netw Open | 2021 |
| 34484350 | High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis. | J Contemp Brachytherapy | 2021 |
| 34049784 | Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis. | Urol Oncol | 2021 |
| 33974058 | Paid Parental Leave Policies Among U.S. News & World Report 2020-2021 Best Hospitals and Best Hospitals for Cancer. | JAMA Netw Open | 2021 |
| 33275486 | Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. | J Clin Oncol | 2021 |
| 33186617 | Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate. | Int J Radiat Oncol Biol Phys | 2021 |
| 33048621 | Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat? | J Clin Oncol | 2021 |
| 33412264 | Drivers of Medicare Spending: A 15-Year Review of Radiation Oncology Charges Allowed by the Medicare Physician/Supplier Fee-for-Service Program Compared With Other Specialties. | Int J Radiat Oncol Biol Phys | 2021 |
| 32396488 | Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. | J Clin Oncol | 2020 |
| 31647971 | Examinations in Radiation Oncology: Listening, Learning, and Looking Forward Together. | Int J Radiat Oncol Biol Phys | 2020 |